Alcediag is a leading personalized medicine company that specializes in mental health. With a primary focus on biomarkers, Alcediag offers a range of innovative products and services to optimize clinical studies and improve outcomes in neuropsychiatry. Their flagship product, EDIT–B, is a groundbreaking blood test that accurately diagnoses bipolar disorder and differentiates it from depression.

In addition, Alcediag's unique platform, EDITECH, enables the discovery and validation of tailor-made biomarkers in various therapeutic areas such as CNS, oncology, and inflammation. With over ten years of research and successful clinical trials, Alcediag is at the forefront of RNA editing, holding registered and granted patents worldwide. Their solutions provide health professionals with simple, objective, and rapid assistance in diagnosing pathologies like depression and bipolar disorder, ultimately leading to accelerated personalized therapeutic decisions and improved patients' quality of life.

Trust Alcediag to revolutionize the field of mental health with their cutting-edge technologies and expertise